Opus Genetics (IRD) risk factors, FY2025 10-K

Risks Related to the Development of Our Gene Therapy Products and Other Product Candidates

1. 01Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval
2. 02Gene therapies are novel, complex and difficult to manufacture. We could experience production problems in our network of external facilities that result in delays in our development or commercialization programs or otherwise adversely affect our business24% rewritten
3. 03In addition to any potential side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our marketing authorization or clinical trials could be suspended or terminatedNew
4. 04A Regenerative Medicine Advanced Therapy designation by the FDA may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that such future product candidate will receive marketing approvalNew
5. 05We may encounter substantial delays in our planned clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
6. 06changes in regulatory requirements and guidance that require amending or submitting new clinical protocols
7. 07We may be negatively impacted if the results of our planned clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates
8. 08The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA
9. 09If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to conduct and complete those clinical trials, and our ability to seek and receive necessary regulatory approvals, could be delayed or prevented
10. 10proximity and availability of clinical trial sites for prospective patients
11. 11Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, which could result in increased costs to us or delays in development timelines
12. 12We may expend a substantial amount of our resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success

Risks Related to the Commercialization of RYZUMVI® and Product Candidates which Obtain Marketing Approval

1. 13We depend heavily on the success of our product pipeline. If we fail to find strategic partners or we (including our strategic partner) fail to adequately commercialize our pipeline products, our business will be materially harmed
2. 14Viatris has exclusive global rights to commercialize RYZUMVI ® and PS in key global markets. Viatris’ failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results
3. 15Viatris may not be able to sublicense RYZUMVI® or PS to one or more suitable parties outside the United States; or67% rewritten
4. 16If we fail to receive regulatory approval for gene therapy treatment of IRDs or any of our planned indications for our non-gene therapy product candidates or fail to develop additional product candidates, our commercial opportunity will be limited
5. 17Even if we do receive regulatory approval for, or successfully commercialize, our product candidates, they will be subject to ongoing regulatory review and critique. This ongoing review and critique may cause the loss of regulatory approval
6. 18We or others could discover that our product candidates lack sufficient efficacy, or sufficient efficacy compared to competitor products or that they cause undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization
7. 19our reputation may suffer generally among both clinicians and patients
8. 20We face substantial competition and rapid technological change, which may result in others discovering, developing, or commercializing products before or more successfully than we do
9. 21We do not currently have any sales or marketing infrastructure in place and may face difficulties in establishing sales and marketing capabilities or engaging third parties to sell, market and distribute our products
10. 22the inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies
11. 23Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, third-party payors, and others in the medical community
12. 24limited genetic testing conducted on potential patients29% rewritten
13. 25If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway
14. 26Our profitability will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business
15. 27Product liability lawsuits against us, or our suppliers and manufacturers, could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop
16. 28the inability to take advantage of limitations on product liability lawsuits that apply to generic drug products, which could increase our exposure to liability for products deemed to be dangerous or defective
17. 29If we or our third-party manufacturers fail to comply with environmental or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business
18. 30We have limited drug research and discovery capabilities and may need to acquire or license product candidates from third parties, raise additional capital, or shift capital resources to expand our product candidate pipeline

Risks Related to Our Financial Position and Need for Additional Capital

1. 31We have not generated significant revenue from sales of any products, expect to incur losses for the foreseeable future and may never achieve or maintain profitability38% rewritten
2. 32achieve market acceptance of our product candidates
3. 33We are a clinical-stage company, and our operations to date have been limited. We have not yet demonstrated our ability to manufacture a product at commercial scale or conduct sales and marketing activities necessary for successful product commercialization
4. 34We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations
5. 35the costs associated with general corporate activities, such as the cost of filing, prosecuting and enforcing patent claims and making regulatory filings
6. 36Worldwide economic and social instability or adverse global economic conditions could adversely affect our revenue, financial condition, or results of operations50% rewritten
7. 37Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates49% rewritten

Risks Related to Government Regulation

1. 38Instability and operational disruptions at government agencies, such as the FDA, may adversely impact our development and commercialization plans by causing delays and requiring the use of additional, unforeseen resources to obtain regulatory approval for trials or products in our pipelineNew
2. 39Even if we receive marketing approval for our product candidates in the United States, we may never receive regulatory approval to market such product candidates outside of the United States
3. 40Legislative reform or changes in the regulatory environment affecting our business may increase the difficulty and cost for obtaining marketing approval of our product candidates, or otherwise affect the pricing and commercial viability of our product candidates
4. 41The biopharmaceutical and medical device industries are subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities41% rewritten
5. 42Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict
6. 43Our employees or representatives may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements, which could significantly harm our business79% rewritten
7. 44The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If found to have improperly promoted off-label uses, we may become subject to significant liability
8. 45Changes to U.S. tax laws and state tax laws, such as those impacting our ability to use our net operating loss carryforwards and certain other tax attributes, may adversely affect our financial condition or results of operations and create the risk that we may need to adjust our accounting for these changes

Risks Related to Our Reliance on Third Parties

1. 46These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control89% rewritten
2. 47collaborators may be unable to obtain the necessary marketing approvals; and28% rewritten
3. 48If we engage in additional acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks

Risks Related to Our Intellectual Property

1. 49We and our licensors have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies and product candidates
2. 50our commercial activities or products will not infringe upon the patents of others
3. 51If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed
4. 52Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates22% rewritten
5. 53We may not be able to protect or practice our intellectual property rights throughout the world
6. 54We are involved in a patent litigation lawsuit with a potential competitor with respect to RYZUMVI® and we may become involved in additional lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful22% rewritten
7. 55Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business
8. 56We may be subject to damages resulting from claims that our employees or consultants have wrongfully misappropriated the intellectual property of their former employers
9. 57If we are not able to adequately prevent disclosure of our trade secrets and other proprietary information, the value of any product we may pursue could be significantly diminished
10. 58Obtaining and maintaining our trademark protection depends on approval from the USPTO and other foreign government agencies, and third parties may challenge, misappropriate, or otherwise weaken our trademark rights
11. 59We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues71% rewritten
12. 60We depend on intellectual property licensed from third parties for development of our product candidates, and the termination of, or reduction or loss of rights under, these licenses would harm our businessNew
13. 61Expansion through obtaining rights to product candidates and approved products through acquisitions may not be successful

Risks Related to Our Employee Matters and Managing Growth

1. 62We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 63We expect that we will need to develop and expand a number of corporate functions in our company (including sales, marketing, and distribution teams), and, as a result, we may encounter difficulties in managing this development and expansion, which could disrupt our operations
3. 64A variety of risks associated with operating internationally for us and our collaborators could adversely affect our business
4. 65changes in diplomatic and trade relationships; and
5. 66Our business and operations could suffer in the event of system failures or unplanned events, including cyber incidents, network security breaches, service interruptions, or data corruption

Risks Related to Ownership of Our Common Stock

1. 67The market price of our common stock is expected to be volatile
2. 68the results of clinical trials of our gene therapy products, PS, or any other product candidate that we may develop73% rewritten
3. 69As of December 31, 2025, we had authority to issue a total of 125.0 million shares of common stock, of which approximately 69.9 million shares had been issued and 48.9 million shares were reserved for issuance pursuant to outstanding stock options, restricted stock units, and warrantsNew
4. 70If we fail to comply with the continued listing standards of Nasdaq, our common stock may be delisted, and our ability to access the capital markets could be negatively impactedNew
5. 71We do not anticipate paying any cash dividends in the foreseeable future24% rewritten
6. 72We may be subject to securities litigation, which is expensive and could divert management attention41% rewritten
7. 73Actions of activist stockholders could adversely affect our business and stock price and cause us to incur significant expenses29% rewritten
8. 74Following our registered direct offering in November 2025, we had authority to issue a total of 125.0 million shares of common stock, of which approximately 69.0 million shares had been issued and 49.8 million shares were reserved for issuance pursuant to outstanding stock options, restricted stock units, and warrantsNew